28th October 2015

Cure Leukaemia can fund the lifesaving work of Just One More specialist research nurse – after a generous donation from Deloitte in Birmingham propelled the total raised during international Blood Cancer Awareness Month past the £50,000 mark.

Cure Leukaemia launched its biggest-ever community fundraising campaign, Just One More, during September in hope of bringing in at least £40,000 – the amount required to fund a nurse for a year.

The Second City and rest of the Midlands region kindly responded to the challenge, with a £25,000 cheque from Deloitte, an official charity partner of Cure Leukaemia since 2013, taking the total to £53,124.

Jackie Kelly, Cure Leukaemia’s Head of Corporate Partnerships, said: “We issued a rallying call to the Midlands region to get behind Just One More and we’re extremely grateful to everyone who has helped us raise such a big total.


Of course, a massive thank you goes to Deloitte, who have been fantastic supporters of our work for the past two years.


Their £25,000 donation will go a long way to funding Just One More specialist research nurse.


The equation is simple: the more nurses we fund, the more blood cancer patients will receive potentially lifesaving treatment.”

Dominic Wong, partner lead for Corporate Responsibility at Deloitte in Birmingham, said:


“Our people nominate, promote and then choose our office charity, which is why they bring so much passion and determination to our fundraising activities.


It’s an absolute pleasure to be supporting Cure Leukaemia, which is doing so much - not just here in the Midlands but in transforming the global field of translational medicine.”

There was a timely reminder during September of the importance of increasing Cure Leukaemia’s Midlands-wide network of nurses, which delivers potentially lifesaving treatments to blood cancer patients who have exhausted all options on the NHS.

Kings Heath resident James Cunningham, aged 70, was diagnosed with Acute Myeloid Leukaemia in June and given just six weeks to live. However, after being placed on a clinical trial administered by Cure Leukaemia-funded nurse Donna Walsh, James is now in remission.


“I’m living proof of the brilliant work the nurses do – without them, I wouldn’t be here,” said James.


“I’ll need bouts of chemotherapy for the rest of my life, but I can live with that after how bleak things looked in June.


Donna’s been amazing. If somebody had told me at my initial diagnosis I’d be in remission a few months later, I wouldn’t have believed it. In fact, I still don’t!”

Just One More received the support of the Second City’s biggest sporting institutions, including Warwickshire CCC, Aston Villa and Birmingham City.

The campaign set out to prove small donations can make a big impact, which was underlined by some of Cure Leukaemia’s regular supporters coming up with simple-but-effective fundraising ideas.

For example, Rewired PR managed to raise over £130 just by donating 5p for every hot drink consumed in the office during Blood Cancer Awareness Month.

Elsewhere, Elonex Outdoor Media held a sponsored ‘Wear it Red’ day while Succeed Academy staged a bake sale.

The team at the Cure Leukaemia office also got involved, raising £150 simply through a creative fines system for each staff member!

Jackie added: “We encouraged the region to come up with simple-but-fun ways to raise money and received great support, with businesses, schools and community groups all getting involved.


We thank everyone who took part in Just One More this year. We’re delighted with the figure that has been raised and look forward to building on it next September.”

WATCH: Just One More campaign videos


< Back to List

What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell